dc.creator | Swerdloff, R. S. | |
dc.creator | Bremner, William J. | |
dc.creator | Wang, C. | |
dc.creator | Anawalt, Bradley D. | |
dc.creator | Berman, N. | |
dc.creator | Steiner, B. | |
dc.creator | Bagatell, Carrie J. | |
dc.date | 2008-10-17T20:41:22Z | |
dc.date | 2008-10-17T20:41:22Z | |
dc.date | 1998-10 | |
dc.date.accessioned | 2012-06-12T05:30:56Z | |
dc.date.available | 2012-06-12T05:30:56Z | |
dc.date.issued | 2012-06-12 | |
dc.identifier | J Clin Endocrinol Metab. 1998 Oct;83(10):3527-33 | |
dc.identifier | http://hdl.handle.net/1773/4350 | |
dc.identifier.uri | https://repositorio.leon.uia.mx/xmlui/1773/4350 | |
dc.description | GnRH antagonists plus testosterone (T) suppress LH and FSH levels and
inhibit spermatogenesis to azoospermia or severe oligozoospermia.
High-dose T treatment alone has been shown to be an effective male
contraceptive (contraceptive efficacy rate of 1.4 per 100 person yr).
Combined GnRH antagonist and T induces azoospermia more rapidly and at a
higher incidence than T alone; this combination has therefore been
proposed as a prototype male contraceptive. However, because GnRH
antagonists are expensive to synthesize and difficult to deliver, it would
be desirable to rapidly suppress sperm counts to low levels with GnRH
antagonist plus T and maintain azoospermia or severe oligozoospermia with
T alone. In this study, 15 healthy men (age 21-41 yr) with normal semen
analyses were treated with T enanthate (TE) 100 mg im/week plus 10 mg
Nal-Glu GnRH antagonist sc daily for 12 weeks to induce azoospermia or
severe oligozoospermia. At 12-16 weeks, 10 of 15 subjects had zero sperm
counts, and 14 of 15 had sperm counts less than 3 x 10(6)/mL. The 14 who
were suppressed on combined treatment were maintained on TE alone (100
mg/week im) for an additional 20 weeks. Thirteen of 14 subjects in the TE
alone phase had sperm counts maintained at less than 3 x 10(6)/mL for 20
weeks. Ten remained persistently azoospermic or had sperm concentration of
0.1 x 10(6)/mL once during maintenance. Mean LH and FSH levels in the
subjects were suppressed to 0.4+/-0.2 IU/L and 0.5+/-0.2 IU/L in the
induction phase, which was maintained in the maintenance phase. The 1
subject who failed to suppress sperm counts during induction had serum LH
and FSH reduced to 0.3 and 0.5 IU/L, respectively. The subject who failed
to maintenance had LH and FSH suppressed to 1.0 and 0.2 IU/L,
respectively, during the induction phase but these rose to 1.6 and 2.1
IU/L, respectively, during maintenance. Failure to suppress or maintain
low sperm counts may be related to incomplete suppression of serum LH and
FSH levels. We conclude that sperm counts suppressed with GnRH antagonist
plus T can be maintained with relatively low dose TE treatment alone. This
concept should be explored further in the development of effective, safe,
and affordable hormonal male contraceptives. | |
dc.language | en_US | |
dc.publisher | Endocrine Society | |
dc.subject | andrology | |
dc.subject | male contraception | |
dc.subject | testosterone | |
dc.subject | colchicine | |
dc.subject | 5-alpha reductase inhibitors | |
dc.subject | spermatogenesis | |
dc.subject | reifenstein's syndrome | |
dc.subject | klinefelter's syndrome | |
dc.subject | gonadotropins | |
dc.subject | Research Support, U.S. Gov't, P.H.S. | |
dc.subject | Luteinizing Hormone, blood | |
dc.subject | Research Support, U.S. Gov't, Non-P.H.S. | |
dc.subject | Spermatogenesis, drug effects | |
dc.subject | Contraceptive Agents, Male, adverse effects, pharmacology | |
dc.subject | Hormone Antagonists, adverse effects, pharmacology | |
dc.subject | Research Support, Non-U.S. Gov't | |
dc.subject | Male | |
dc.subject | Testosterone, adverse effects, analogs & derivatives, blood, pharmacology | |
dc.subject | Libido, drug effects | |
dc.subject | Follicle Stimulating Hormone, blood | |
dc.subject | Adult | |
dc.subject | Dipeptides, adverse effects, pharmacology | |
dc.subject | Sexual Behavior, drug effects | |
dc.subject | Humans | |
dc.subject | Gonadorelin, antagonists & inhibitors | |
dc.title | Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone | |
dc.type | Article | |